{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:59:22Z","timestamp":1791233962939,"version":"4.1.0"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000296","name":"British Skin Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000296","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MR\/V023373\/1"],"award-info":[{"award-number":["MR\/V023373\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023699","name":"Health Data Research UK","doi-asserted-by":"publisher","award":["LOND1"],"award-info":[{"award-number":["LOND1"]}],"id":[{"id":"10.13039\/501100023699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010756","name":"Health and Social Care Research and Development Division","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001626","name":"Public Health Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001626","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evidence suggests an association between atopic eczema (AE) or psoriasis and mental illness; however, the factors associated with mental illness are unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To synthesize and evaluate all available evidence on factors associated with depression, anxiety and severe mental illness (SMI) among adults with AE or psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched electronic databases, grey literature databases and clinical trial registries from inception to February 2022 for studies of adults with AE or psoriasis. Eligible studies included randomized controlled trials (RCTs), cohort, cross-sectional or case\u2013control studies where effect estimates of factors associated with depression, anxiety or SMI were reported. We did not apply language or geographical restrictions. We assessed risk of bias using the Quality in Prognosis Studies tool. We synthesized results narratively, and if at least two studies were sufficiently homogeneous, we pooled effect estimates in a random effects meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 21 studies (11 observational, 10 RCTs). No observational studies in AE fulfilled our eligibility criteria. Observational studies in people with psoriasis mostly investigated factors associated with depression or anxiety \u2013 one cross-sectional study investigated factors associated with schizophrenia. Pooled effect estimates suggest that female sex and psoriatic arthritis were associated with depression [female sex: odds ratio (OR) 1.62, 95% confidence interval (CI) 1.09\u20132.40, 95% prediction intervals (PIs) 0.62\u20134.23, I2 = 24.90%, \u03c42 = 0.05; psoriatic arthritis: OR 2.26, 95% CI 1.56\u20133.25, 95% PI 0.21\u201324.23, I2 = 0.00%, \u03c42 = 0.00] and anxiety (female sex: OR 2.59, 95% CI 1.32\u20135.07, 95% PI 0.00\u20133956.27, I2 = 61.90%, \u03c42 = 0.22; psoriatic arthritis: OR 1.98, 95% CI 1.33\u20132.94, I2 = 0.00%, \u03c42 = 0.00). Moderate\/severe psoriasis was associated with anxiety (OR 1.14, 95% CI 1.05\u20131.25, I2 0.00%, \u03c42 = 0.00), but not depression. Evidence from RCTs suggested that adults with AE or psoriasis given placebo had higher depression and anxiety scores compared with comparators given targeted treatment (e.g. biologic agents).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our review highlights limited existing research on factors associated with depression, anxiety and SMI in adults with AE or psoriasis. Observational evidence on factors associated with depression or anxiety in people with psoriasis was conflicting or from single studies, but some identified factors were consistent with those in the general population. Evidence on factors associated with SMIs in people with AE or psoriasis was particularly limited. Evidence from RCTs suggested that AE and psoriasis treated with placebo was associated with higher depression and anxiety scores compared with skin disease treated with targeted therapy; however, follow-up was limited. Therefore, long-term effects on mental health are unclear.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljac132","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T09:21:10Z","timestamp":1674206470000},"page":"460-470","source":"Crossref","is-referenced-by-count":55,"title":["Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"188","author":[{"given":"Elizabeth I","family":"Adesanya","sequence":"first","affiliation":[{"name":"Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Matthewman","sequence":"additional","affiliation":[{"name":"Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yochai","family":"Schonmann","sequence":"additional","affiliation":[{"name":"Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev , Beer Sheva , Israel"},{"name":"Department of Quality Measurements and Research , Clalit Health Services, Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-3862","authenticated-orcid":false,"given":"Joseph F","family":"Hayes","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8903-4906","authenticated-orcid":false,"given":"Alasdair","family":"Henderson","sequence":"additional","affiliation":[{"name":"Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Mathur","sequence":"additional","affiliation":[{"name":"Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy R","family":"Mulick","sequence":"additional","affiliation":[{"name":"Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H","family":"Smith","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guys and St Thomas\u2019 Foundation Trust and King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin\u00e9ad M","family":"Langan","sequence":"additional","affiliation":[{"name":"Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine , London , UK"},{"name":"Health Data Research UK , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E","family":"Mansfield","sequence":"additional","affiliation":[{"name":"Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"2023100916152814900_ljac132-B1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"2023100916152814900_ljac132-B2","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"2023100916152814900_ljac132-B3","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"James","year":"2018","journal-title":"Lancet"},{"key":"2023100916152814900_ljac132-B4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2017.04.019","article-title":"Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey","volume":"77","author":"Eckert","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2023100916152814900_ljac132-B5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.24869\/psyd.2017.401","article-title":"Analysis of the prevalence of mental disorders in psoriasis: the relevance of psychiatric assessment in dermatology","volume":"29","author":"Ferreira","year":"2017","journal-title":"Psychiatr Danub"},{"key":"2023100916152814900_ljac132-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dsi.2016.07.005","article-title":"Prevalence of schizophrenia in patients with psoriasis: a nationwide study","volume":"35","author":"Tu","year":"2017","journal-title":"Dermatologica Sin"},{"key":"2023100916152814900_ljac132-B7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaci.2012.10.041","article-title":"Mental health comorbidity in patients with atopic dermatitis","volume":"131","author":"Yaghmaie","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2023100916152814900_ljac132-B8","first-page":"235","article-title":"Psychiatric morbidity in dermatological outpatients: an issue to be recognized","volume":"17","author":"Aslam","year":"2007","journal-title":"J Pakistan Assoc Dermatologists"},{"key":"2023100916152814900_ljac132-B9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jaip.2019.08.030","article-title":"Atopic eczema in adulthood and risk of depression and anxiety: a population-based cohort study","volume":"8","author":"Schonmann","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2023100916152814900_ljac132-B10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2340\/00015555-2183","article-title":"Psoriasis and new-onset depression: a Danish nationwide cohort study","volume":"96","author":"Jensen","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"2023100916152814900_ljac132-B11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jad.2016.06.012","article-title":"Risk of developing major depression and bipolar disorder among adolescents with atopic diseases: a nationwide longitudinal study in Taiwan","volume":"203","author":"Wei","year":"2016","journal-title":"J Affect Disord"},{"key":"2023100916152814900_ljac132-B12","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bjd.19597","article-title":"Atopic eczema and obesity: a population-based study","volume":"184","author":"Ascott","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023100916152814900_ljac132-B13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ad.2012.08.003","article-title":"Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications","volume":"105","author":"Carrascosa","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"2023100916152814900_ljac132-B14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jaad.2016.07.017","article-title":"Association of atopic dermatitis with smoking: a systematic review and meta-analysis","volume":"75","author":"Kantor","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2023100916152814900_ljac132-B15","first-page":"65","article-title":"Psoriasis and smoking: links and risks","volume":"6","author":"Naldi","year":"2016","journal-title":"Psoriasis (Auckl)"},{"key":"2023100916152814900_ljac132-B16","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bjd.15674","article-title":"High prevalence of alcohol use disorders in patients with inflammatory skin diseases applies to both psoriasis and eczema","volume":"177","author":"Gisondi","year":"2017","journal-title":"Br J Dermatol"},{"key":"2023100916152814900_ljac132-B17","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/bjd.13169","article-title":"Association between tobacco smoking and prognosis of occupational hand eczema: a prospective cohort study","volume":"171","author":"Brans","year":"2014","journal-title":"Br J Dermatol"},{"key":"2023100916152814900_ljac132-B18","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.5694\/mja12.10508","article-title":"Depression, diet and exercise","volume":"199","author":"Jacka","year":"2013","journal-title":"Med J Aust"},{"key":"2023100916152814900_ljac132-B19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/1745017901612010067","article-title":"Associations between anxiety disorder diagnoses and body mass index differ by age, sex and race: a population based study","volume":"12","author":"DeJesus","year":"2016","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"2023100916152814900_ljac132-B20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/7854_2015_367","article-title":"Chronically restricted or disrupted sleep as a causal factor in the development of depression","volume":"25","author":"Meerlo","year":"2015","journal-title":"Curr Top Behav Neurosci"},{"key":"2023100916152814900_ljac132-B21","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000490002","article-title":"Inflammation: a contributor to depressive comorbidity in inflammatory skin disease","volume":"31","author":"Farzanfar","year":"2018","journal-title":"Skin Pharmacol Physiol"},{"key":"2023100916152814900_ljac132-B22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40257-017-0279-8","article-title":"Psoriasis, depression, and inflammatory overlap: a review","volume":"18","author":"Patel","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"2023100916152814900_ljac132-B23","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fnins.2015.00372","article-title":"The role of inflammation in schizophrenia","volume":"9","author":"M\u00fcller","year":"2015","journal-title":"Front Neurosci"},{"key":"2023100916152814900_ljac132-B24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pbb.2018.12.006","article-title":"Revisiting inflammation in bipolar disorder","volume":"177","author":"Fries","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"2023100916152814900_ljac132-B25","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s11606-011-1704-y","article-title":"Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis","volume":"26","author":"Grenard","year":"2011","journal-title":"J Gen Intern Med"},{"key":"2023100916152814900_ljac132-B26","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2023100916152814900_ljac132-B27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038324","article-title":"Risk factors for mental illness in adults with atopic eczema or psoriasis: protocol for a systematic review","volume":"10","author":"Adesanya","year":"2020","journal-title":"BMJ Open"},{"key":"2023100916152814900_ljac132-B28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1477-7525-1-29","article-title":"The Hospital Anxiety and Depression Scale","volume":"1","author":"Snaith","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"2023100916152814900_ljac132-B29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"key":"2023100916152814900_ljac132-B30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"2023100916152814900_ljac132-B31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2023100916152814900_ljac132-B32","author":"Higgins"},{"key":"2023100916152814900_ljac132-B33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/2046-4053-1-34","article-title":"A note on the graphical presentation of prediction intervals in random-effects meta-analyses","volume":"1","author":"Guddat","year":"2012","journal-title":"Syst Rev"},{"key":"2023100916152814900_ljac132-B34","first-page":"491","article-title":"Depression and anxiety among patients with psoriasis: A correlation with quality of life and associated factors","volume":"16","author":"Bakar","year":"2021","journal-title":"J Taibah Univ Med Sci"},{"key":"2023100916152814900_ljac132-B35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00403-018-1832-x","article-title":"Determinants of quality of life and psychological status in adults with psoriasis","volume":"310","author":"Kwan","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"2023100916152814900_ljac132-B36","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jaclp.2021.12.007","article-title":"Depression and suicidality in patients with psoriasis and the role of psoriatic arthritis: a cross-sectional study in a tertiary setting","volume":"63","author":"Lada","year":"2022","journal-title":"J Acad Consult Liaison Psychiatry"},{"key":"2023100916152814900_ljac132-B37","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.medici.2016.07.001","article-title":"Associations of the quality of life and psychoemotional state with sociodemographic factors in patients with psoriasis","volume":"52","author":"Petra\u0161kien\u0117","year":"2016","journal-title":"Medicina (Kaunas"},{"key":"2023100916152814900_ljac132-B38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2017.08.051","article-title":"Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"78","author":"Strober","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023100916152814900_ljac132-B39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/13548506.2018.1529323","article-title":"A Chinese cross-sectional study on depression and anxiety symptoms in patients with psoriasis vulgaris","volume":"24","author":"Tian","year":"2019","journal-title":"Psychol Health Med"},{"key":"2023100916152814900_ljac132-B40","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2340\/00015555-3114","article-title":"Patients with moderate to severe psoriasis associate with higher risk of depression and anxiety symptoms: results of a multivariate study of 300 Spanish individuals with psoriasis","volume":"99","author":"Trib\u00f3","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"2023100916152814900_ljac132-B41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dsi.2016.07.005","article-title":"Prevalence of schizophrenia in patients with psoriasis: a nationwide study","volume":"35","author":"Tu","year":"2017","journal-title":"Dermatologica Sin"},{"key":"2023100916152814900_ljac132-B42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2340\/00015555-2483","article-title":"Gender, Body image and social support: biopsychosocial determinants of depression among patients with psoriasis","volume":"97","author":"Wojtyna","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2023100916152814900_ljac132-B43","first-page":"685","article-title":"A study on the relationship between gender and depression incidence in patients with psoriasis","volume":"44","author":"Yu","year":"2015","journal-title":"J Clin Dermatol"},{"key":"2023100916152814900_ljac132-B44","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/bjd.14833","article-title":"Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting","volume":"176","author":"Lamb","year":"2017","journal-title":"Br J Dermatol"},{"key":"2023100916152814900_ljac132-B45","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9)","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"2023100916152814900_ljac132-B46","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2023100916152814900_ljac132-B47","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"376","author":"Simpson","year":"2017","journal-title":"N Engl J Med"},{"key":"2023100916152814900_ljac132-B48","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/09546634.2019.1612836","article-title":"Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2","volume":"31","author":"Cork","year":"2020","journal-title":"J Dermatolog Treat"},{"issue":"Suppl. 1","key":"2023100916152814900_ljac132-B49","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1097\/DER.0000000000000725","article-title":"Patient-reported symptoms and disease impacts in adults with moderate-to-severe atopic dermatitis: results from a phase 2b study with abrocitinib","volume":"32","author":"Simpson","year":"2021","journal-title":"Dermatitis"},{"key":"2023100916152814900_ljac132-B50","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1111\/jdv.15012","article-title":"Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the phase 3 VOYAGE 2 study","volume":"32","author":"Gordon","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100916152814900_ljac132-B51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000479163","article-title":"Impact of ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis: an integrated analysis of three phase 3 clinical studies","volume":"86","author":"Griffiths","year":"2017","journal-title":"Psychother Psychosom"},{"key":"2023100916152814900_ljac132-B52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2009.09.014","article-title":"Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial","volume":"63","author":"Langley","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"2023100916152814900_ljac132-B53","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jaad.2009.07.022","article-title":"The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial","volume":"62","author":"Menter","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"2023100916152814900_ljac132-B54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"2023100916152814900_ljac132-B55","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Syn Methods"},{"key":"2023100916152814900_ljac132-B56","first-page":"65","article-title":"The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA","volume":"8","author":"Walsh","year":"2018","journal-title":"Psoriasis (Auckl)"},{"key":"2023100916152814900_ljac132-B57","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2023100916152814900_ljac132-B58","doi-asserted-by":"crossref","DOI":"10.1016\/B0-12-369398-5\/00038-4","volume-title":"Non-Response Bias","author":"Berg","year":"2005"},{"issue":"794","key":"2023100916152814900_ljac132-B59","article-title":"Risk factors, prevalence, and treatment of anxiety and depressive disorders in Pakistan: systematic review","volume":"328","author":"Mirza","year":"2004","journal-title":"BMJ"},{"key":"2023100916152814900_ljac132-B60","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1192\/bjp.bp.115.169094","article-title":"Social support and protection from depression: systematic review of current findings in Western countries","volume":"209","author":"Gari\u00e9py","year":"2016","journal-title":"Br J Psychiatry"},{"key":"2023100916152814900_ljac132-B61","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/916198","article-title":"Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review","volume":"2012","author":"Ochoa","year":"2012","journal-title":"Schizophr Res Treatment"},{"key":"2023100916152814900_ljac132-B62","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2337\/diacare.24.6.1069","article-title":"The prevalence of comorbid depression in adults with diabetes: a meta-analysis","volume":"24","author":"Anderson","year":"2001","journal-title":"Diabetes Care"},{"key":"2023100916152814900_ljac132-B63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/all.14510","article-title":"Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"2023100916152814900_ljac132-B64","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/jdv.12909","article-title":"Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review","volume":"29","author":"Fleming","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100916152814900_ljac132-B65","first-page":"36","article-title":"Psoriasis and associated psychiatric disorders: a systematic review on etiopathogenesis and clinical correlation","volume":"9","author":"Ferreira","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"2023100916152814900_ljac132-B66","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000448122","article-title":"Major depression and psoriasis: a psychodermatological phenomenon","volume":"29","author":"Tohid","year":"2016","journal-title":"Skin Pharmacol Physiol"},{"key":"2023100916152814900_ljac132-B67","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.autrev.2006.12.002","article-title":"Biologic therapies in psoriasis: a new therapeutic approach","volume":"6","author":"Gisondi","year":"2007","journal-title":"Autoimmun Rev"},{"key":"2023100916152814900_ljac132-B68","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4168\/aair.2016.8.3.181","article-title":"A comprehensive review of the treatment of atopic eczema","volume":"8","author":"Lee","year":"2016","journal-title":"Allergy Asthma Immunol Res"},{"key":"2023100916152814900_ljac132-B69","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2018.03.017","article-title":"Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis","volume":"79","author":"R\u00f8nnstad","year":"2018","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljac132\/49103467\/ljac132.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/4\/460\/51961110\/ljac132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/4\/460\/51961110\/ljac132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T12:22:05Z","timestamp":1696854125000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/188\/4\/460\/6931836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":69,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12,19]]},"published-print":{"date-parts":[[2023,3,30]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljac132","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,12,19]]}}}